

OHMR Research Ethics and Governance Metrics Program



Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 2 2024
01/04/2024 – 30/06/2024

NSW Office for Health and Medical Research



Executive Summary

This report includes strategic and site level performance and compliance metrics that are collected by the Office for Health and Medical Research (OHMR) from NSW Public Health Organisations (PHOs) on studies authorised during the reporting period. The performance of NSW PHOs on health and medical research are reported four times a year, each covering a 3-month period.

Overall Performance Environment

REGIS is the online platform used to manage ethics and governance applications for all NSW Public Health Organisations. OHMR has undertaken data validation activities with LHD Research Office staff to accurately represent research ethics and governance performance on this platform. These rolling validation activities may result in data reported here to differ from previous reports.

Update to Metrics Program

As reported previously, OHMR implemented the following changes to the Research Key Performance Indicators (KPIs) for inclusion in the Chief Executives' Services Agreement:

- Number of Greater than Low Risk projects (GLR) processed within application total time
 - 90 days for ethics, 60 days for governance
 - Threshold changes
 - >75% = Performing
 - 55%-75% = Underperforming
 - <55% = Not performing



Ethics Review Timelines of Human Research in NSW PHOs

KPI21-03: Ethics Application Approvals - By the Human Research Ethics Committee (HREC) within 90 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards is for reviewing human research studies by NSW PHO HRECs within 90 calendar days

Definition:

The proportion of Ethics applications (excluding LNR) approved by the HREC within 90 calendar days, approved within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the NHMRC Certification Handbook. Instead, the end-to-end time will be measured. Where a valid application is received, the clock starts on the submission closing date for the HREC meeting at which an application will be reviewed. The clock is stopped when the HREC formally notifies the applicant of the final decision.

Desired Outcome:

Ensuring timely processing of ethics approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope	Human Research Ethics Applications
Frequency	Quarterly
Inclusions	<ul style="list-style-type: none"> Study Type = All Application Type = Greater than low risk Approval Type = Approved/ Approved with conditions within the reporting period
Exclusions	<ul style="list-style-type: none"> Application Type = Low and negligible risk Approval Type = Not within the reporting period Migrated studies

Total

Total time is defined as the measurement of the total, unadjusted time from the Submission Closing Date of the first meeting the application is assigned to, to when the final decision notification email is sent.

Summary for Metric 3


Ethics review performance of NSW HRECs according to the < **90-day benchmark** for studies approved during the reporting period (**Quarter 2 2024**) are shown in **Table 1**.

During the reporting period, 245 studies (greater than low risk pathway) were approved by a NSW Health HREC with an average review time (total time) of 54 days. Of these 245 studies, 98 (40%) were classified as clinical trials (**Table 2**).




Further breakdown of clinical trial approvals by sponsor type is provided in **Table 3** (by NSW PHOs) and **Table 4** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications is presented in **Table 5**.

Trend of **Average Research Office Days** and **Average Researcher Days** for all GLR Ethics Approval over the reporting period Q1 2022- Q2 2024





— Research Office — Researcher





— Research Office — Researcher




— ResearchOffice — Researcher




Overall breakdown and breakdown by NSW LHDs by **Sponsor Types** of Ethics Approvals for reporting period Q2 2024.



Average total time (days) for Clinical trial approvals by sponsor type trends between Q1 2022 and Q2 2024 in NSW.



Average research office time (days) for Clinical Trial approvals by Sponsor type trends between Q1 2022 and Q2 2024.





Site-specific Assessment (SSA) Authorisation Timelines of Human Research Projects in NSW PHOs

KPI21-04: Research Governance Application Authorisations – SSA Authorisations within 60 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards for authorisation of SSA applications is 60 calendar days

Definition:

The proportion of site-specific assessment (SSA) applications (excluding lower to negligible risk) authorised by the Research Governance Office (RGO) within 60 calendar days, authorised within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the National Health and Medical Research Council Certification Handbook. Instead, the end-to-end time will be measured. The SSA application received date is the date the RGO or designee receives an SSA application from a researcher regardless of whether it is complete and/or deemed valid. The clock is stopped when the final SSA decision letter is provided to the site principal investigator.

Desired Outcome:

Ensuring timely processing of site approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope

Site-specific assessment (SSA) applications

Frequency

Quarterly

Inclusions

- Study Type = All
- Application Type = Greater than low risk
- Approval Type = “Authorised” or “authorised with conditions” within the reporting period

Exclusions

- Application Type = Low and negligible risk
- Migrated studies

Total Time:

Total time is the measurement of the total, unadjusted time from the Submission Date to when the final decision notification email is sent granting approval.





Summary:

SSA review performance of NSW PHOs according to the **<60-day benchmark** for studies authorised during the reporting period (**Quarter 2 2024**) are shown in **Table 6**. During the reporting period, **576** studies (greater than low risk pathway) were authorised in NSW PHOs with an average review time (total time) of **45** days.




Of these **576** studies, **261** were classified as clinical trials (**Table 7**). Further breakdown of clinical trial SSA authorisations by sponsor type is provided in **Table 8** (by NSW PHOs) and **Table 9** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of governance applications is presented in **Table 10**.

Trend of **Average Research Office days** and **Average Researcher days** for all GLR SSAs Authorisations by LHD over reporting period Q12022 - Q2 2024







— Research Office — Researcher





— Research Office — Researcher




— Research Office — Researcher




Overall breakdown and breakdown by LHDs of SSA Authorisations by **Sponsor Types** for reporting period Q2 2024.



Average total time (days) for Clinical Trials Authorisation by Sponsor Type trends between Q3 2021 and Q2 2024







Average research office time (DAYS) for Clinical Trial Authorisation by Sponsor type trends between Q3 2021 and Q2 2024











Trends of performance for NSW PHO's SSA Authorisations within 60 days







LHD NSW




— LHD — NSW




— LHD — NSW




Breakdown of **Sponsor Type** of all GLR SSA Authorisations by Site




Breakdown of **Sponsor Type** of all GLR SSA Authorisations by Site



Breakdown of **Study Types** for all GLR SSA Authorisations by Site



Breakdown of **Study Types** for all GLR SSA Authorisations by Site



A list of NSW PHOs names and abbreviations that review and/or authorise human research studies:

Human Research Ethics Committee/ Research Governance Office Names	Abbreviation used in the tables	Ethics	Site
Ambulance Service of NSW	ASNSW		Yes
Bellberry	BLLBRRY	Yes	
Calvary Mater Hospital Newcastle	CALVARY		Yes
Central Coast LHD	CCLHD		Yes
NSW Population & Health Services Research Ethics Committee	CINSW	Yes	
Greater Western LHD	WNSWLHD	Yes	Yes
Hammond Care	HCARE		Yes
Hunter New England LHD	HNELHD	Yes	Yes
Justice Health & Forensic Mental Health Network	JHFMHN	Yes	Yes
Mid North Coast LHD	MNCLHD		Yes
Murrumbidgee LHD	MLHD		Yes
Northern NSW LHD	NNSWLHD	Yes	Yes
Nepean Blue Mountains LHD	NBMLHD	Yes	Yes
Northern Sydney LHD	NSLHD	Yes	Yes
NSW Health Pathology	NSWHPTH		Yes
Royal Rehabilitation Centre Sydney HREC	RRCS	Yes	
Sydney Children's Hospitals Network	SCHN	Yes	Yes
South Eastern Sydney LHD	SESLHD	Yes	Yes
Sydney LHD (Concord Zone)	SLHD – CCD	Yes	Yes
Sydney LHD (RPAH Zone)	SLHD – RPA	Yes	Yes
Southern NSW LHD	SNSWLHD		Yes
St Vincent's Hospital	SVHN	Yes	Yes
South Western Sydney LHD	SWSLHD	Yes	Yes
Illawarra Shoalhaven LHD (joint committee with University of Wollongong)	ISLHD	Yes	Yes
Western Sydney LHD	WSLHD	Yes	Yes



For more information

This report has been prepared by the Research Ethics and Governance Unit in Office for Health and Medical Research.

For further enquiries and for the use of this report please contact:

James Cokayne

Principal Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9391 9920](tel:(02)93919920) | james.cokayne@health.nsw.gov.au

Ambika V Murthy

Senior Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9461 7887](tel:(02)94617887) | Ambika.murthy@health.nsw.gov.au

Deb Aldridge

Policy Officer and Data Analyst

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 93919854](tel:(02)93919854) | deborah.aldridge@health.nsw.gov.au

OHMR Research Ethics and Governance Metrics Program Appendix 1



Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 2 2024
01/04/2024 – 30/06/2024

NSW Office for Health and Medical Research



Table 1. The 90 calendar days benchmark for approval of human research ethics applications (**greater than low risk**) during the reporting period.

Ethics Approval (Q2 2024)						
All greater than low risk applications						
NSW PHOS	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	33	30	91%	46	25	21
CINSW	7	5	71%	103	46	57
HNELHD	23	23	100%	28	16	12
ISLHD	0	0	-	-	-	-
JHFMHN	0	0	-	-	-	-
NBMLHD	3	3	100%	59	47	12
NNSWLHD	3	1	33%	195	69	126
NSLHD	33	33	100%	30	14	17
SCHN	19	10	53%	99	42	57
SESLHD	13	12	92%	63	43	21
SLHD-CCD	8	8	100%	62	24	38
SLHD-RPA	35	34	97%	52	23	29
SVHN	21	13	62%	82	37	45
SWSLHD	18	12	67%	90	67	23
WNSWLHD	8	7	88%	55	28	27
WSLHD	21	16	76%	75	43	32
TOTAL	245	207	84%	54	33	20

Table 2. The 90 calendar days benchmark for the approval of clinical trials (greater than low risk) during the reporting period.

Ethics Approval (Q2 2024)						
Clinical Trials						
NSW PHOs	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	33	30	91%	46	25	21
CINSW	0	0	-	-	-	-
HNELHD	7	7	100%	24	15	9
ISLHD	0	0	-	-	-	-
JHFMHN	0	0	-	-	-	-
NBMLHD	1	1	100%	59	55	4
NNSWLHD	0	0	-	-	-	-
NSLHD	8	8	100%	49	16	34
SCHN	4	2	50%	112	40	72
SESLHD	4	4	100%	56	45	11
SLHD-CCD	4	4	100%	64	24	40
SLHD-RPA	9	8	89%	72	33	39
SVHN	13	8	62%	71	36	35
SWSLHD	4	3	75%	79	44	36
WNSWLHD	1	1	100%	47	41	6
WSLHD	11	7	64%	75	43	32
TOTAL	98	77	79%	59	30	29

Table 3. Breakdown of NSW PHO performances in **clinical trial approvals** (greater than low risk) during the reporting period **by sponsor type**

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average	Average	Total # of Applications	Average	Average	Total # of Applications	Average	Average
		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)
BLLBRY	0	-	-	32	25	46	1	29	57
CINSW	0	-	-	0	-	-	0	-	-
HNELHD	3	16	32	0	-	-	3	12	16
ISLHD	0	-	-	0	-	-	0	-	-
JHFMHN	0	-	-	0	-	-	0	-	-
NBMLHD	0	-	-	0	-	-	1	55	59
NNSWLHD	0	-	-	0	-	-	0	-	-
NSLHD	0	-	-	2	27	61	6	12	46
SCHN	1	35	57	1	46	70	2	39	161
SESLHD	1	33	47	1	40	49	2	54	65
SLHD-CCD	1	21	64	1	22	84	2	27	54
SLHD-RPA	5	30	73	2	45	77	2	30	68
SVHN	3	33	77	5	39	73	5	35	65
SWSLHD	0	-	-	3	43	60	1	45	137
WNSWLHD	0	-	-	0	-	-	1	41	47
WSLHD	0	-	-	9	43	66	2	39	117
Grand Total	14	28	61	56	31	55	28	30	67

Table 4. Quarterly clinical trial approvals (greater than low risk) in the last 3 reporting period (between 01/10/2023 and 30/06/2024), by sponsor type

	Q4 2023			Q1 2024			Q2 2024		
Sponsor Type	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
Collaborative Group	15	24	41	10	48	77	14	28	61
Commercial Entity	44	34	55	46	32	59	56	31	55
Investigator Initiated	17	22	41	28	31	57	28	30	67
Total	76	26	43	84	26	43	98	26	43

Table 5. Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications (greater than low risk) in the last 3 reporting period (between 01/10/2023 and 30/06/2024).

NSW PHO	Q4 2023							Q1 2024							Q2 2024						
	Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)		
		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)
BLLBRRY	23	21	91%	17	21	91%	47	29	23	79%	23	26	90%	50	33	30	91%	21	30	91%	46
CINNSW	5	4	80%	34	4	80%	74	3	1	33%	66	0	0%	101	7	5	71%	57	5	71%	103
HNELHD	32	32	100%	7	32	100%	23	14	14	100%	8	14	100%	28	23	23	100%	12	23	100%	28
ISLHD	0	0	0%	0	0	0%	0	0	0	0%	0	0	0%	0	0	0	-	-	0	-	-
JHFMHN	4	4	100%	8	4	100%	46	3	0	0%	75	3	100%	75	0	0	-	-	0	-	-
NBMLHD	3	3	100%	16	3	100%	45	2	1	50%	24	2	100%	49	3	3	100%	12	3	100%	59
NNSWLHD	1	1	100%	38	1	100%	70	3	2	67%	64	1	33%	116	3	1	33%	126	1	33%	195
NSLHD	39	38	9%	15	39	100%	34	30	27	90%	18	30	100%	32	33	30	91%	17	33	100%	30
SCHN	7	7	100%	17	7	100%	44	12	8	67%	34	9	75%	60	19	10	53%	57	10	53%	99
SESLHD	11	10	91%	16	8	73%	66	15	12	80%	28	10	67%	81	13	12	92%	21	12	92%	63
SLHD-CCD	14	10	71%	32	14	100%	54	8	4	50%	41	8	100%	67	8	6	75%	38	8	100%	62
SLHD-RPA	43	42	98%	15	43	100%	34	26	23	88%	23	26	100%	54	35	30	86%	29	34	97%	52
SVHN	31	20	65%	47	22	71%	78	16	12	75%	31	12	81%	69	21	11	52%	45	13	62%	82
SWSLHD	16	16	100%	15	11	69%	74	15	12	80%	36	8	53%	111	18	16	89%	23	12	67%	90
WNSWLHD	4	3	75%	27	2	50%	79	9	6	67%	39	6	67%	74	8	6	75%	27	7	88%	55
WSLHD	16	12	75%	35	12	75%	78	24	13	54%	45	13	54%	85	21	15	71%	32	16	76%	75
TOTAL	249	223	90%	21	223	88%	54	209	158	76%	21	169	88%	54	245	198	81%	21	207	80%	54

Table 6: The 60 calendar days benchmark for authorisation of governance applications (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q2 2024)							
	All greater than low risk applications							
		60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
	Total Number of Applications	Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	1	0	0%	234	0	137	97	0
Calvary	9	9	100%	16	13	1	1	0
CCLHD	12	10	83%	49	5	20	0	22
FWLHD	0	0	-	-	-	-	-	-
HNELHD	34	34	100%	25	9	4	2	14
ISLHD	19	16	84%	24	3	11	1	13
JHFMHN	2	1	50%	45	4	37	0	5
MLHD	8	8	100%	30	2	11	3	15
MNCLHD	9	8	89%	43	10	8	18	8
NBMLHD	9	5	56%	68	37	12	3	17
NNSWLHD	0	0	-	-	-	-	-	-
NSLHD	52	49	94%	34	10	7	4	17
NSWHPTH	9	1	11%	141	34	44	2	61
SCHN	46	34	74%	52	15	14	0	23
SESLHD	57	54	95%	37	12	7	0	19
SLHD-CCD	28	28	100%	19	5	3	5	6
SLHD-RPA	57	57	100%	25	5	10	4	7
SNSWLHD	6	4	67%	301	23	7	12	260
SVHN	42	31	74%	48	10	10	1	28
SWSLHD	133	97	73%	51	15	15	1	31
WNSWLHD	12	11	92%	23	5	4	0	14
WSLHD	31	23	74%	42	9	9	1	27
TOTAL	576	486	84%	45	13	11	2	23

Table 7: The 60 calendar days benchmark for the authorisation of clinical trials (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q2 2024) Clinical Trials							
	Total Number of Applications	60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
		Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
CALVARY	9	9	100%	16	13	1	1	0
CCLHD	8	6	75%	54	5	22	0	27
FWLHD	0	0	-	-	-	-	-	-
HNELHD	9	9	100%	34	11	9	3	12
ISLHD	9	8	89%	20	3	14	1	2
JHFMHN	0	0	-	-	-	-	-	-
MLHD	0	0	-	-	-	-	-	-
MNCLHD	4	4	100%	36	9	7	20	0
NBMLHD	4	2	50%	74	50	21	3	1
NNSWLHD	0	0	-	-	-	-	-	-
NSLHD	21	19	90%	32	10	7	3	13
NSWHPH	1	0	0	180	55	23	3	99
SCHN	14	10	71%	64	26	15	1	23
SESLHD	29	29	100%	36	13	8	0	15
SLHD-CCD	12	12	100%	22	6	6	9	1
SLHD-RPA	19	19	100%	33	5	11	11	7
SNSWLHD	5	3	60%	352	22	7	12	311
SVHN	23	16	70%	51	11	9	2	30
SWSLHD	81	63	78%	48	15	15	1	24
WNSWLHD	3	3	100%	31	10	5	0	16
WSLHD	10	7	70%	36	4	7	1	24
TOTAL	261	222	85%	49	15	11	3	23

Table 8. NSW PHO performances in clinical trial authorisations (greater than low risk) during the reporting period, by sponsor type.

NSW PHOs	Collaborative group			Commercial entity			Investigator-initiated		
	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
ASNSW	0	-	-	0	-	-	0	-	-
CALVARY	3	14	16	6	13	15	0	-	-
CCLHD	3	3	28	2	4	10	3	8	109
FWLHD	0	-	-	0	-	-	0	-	-
HNELHD	4	10	40	3	9	23	2	16	38
ISLHD	2	3	44	6	4	15	1	2	5
JHFMHN	0	-	-	0	-	-	0	-	-
MLHD	0	-	-	0	-	-	0	-	-
MNCLHD	0	-	-	4	9	36	0	-	-
NBMLHD	2	47	88	1	56	63	1	51	58
NNSWLHD	0	-	-	0	-	-	0	-	-
NSLHD	8	9	35	5	11	23	8	10	36
NSWHPTH	0	-	-	0	-	-	0	-	-
SCHN	4	22	67	5	29	49	5	27	78
SESLHD	8	12	44	17	14	29	4	13	45
SLHD-CCD	2	2	13	9	4	22	1	29	38
SLHD-RPA	6	1	38	10	6	27	3	11	41
SNSWLHD	2	37	89	0	-	-	3	12	528
SVHN	3	14	66	15	9	41	5	15	75
SWSLHD	12	29	74	52	8	31	17	27	80
WNSWLHD	0	-	-	2	8	25	1	14	44
WSLHD	3	8	71	4	1	13	3	3	32
Total	63	16	51	141	11	30	56	25	94

Table 9. Quarterly clinical trial authorisations (greater than low risk applications) approved during the last 3 reporting period, by sponsor type

	Q4 2023			Q1 2024			Q2 2024		
Sponsor Type	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time
Collaborative Group	69	24	51	48	28	63	63	16	51
Commercial Entity	140	17	35	105	20	42	141	11	30
Investigator Initiated	59	15	53	40	20	60	56	25	94
Total	268	18	47	193	22	47	260	15	47

Table 10. Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of SSA applications (greater than low risk) for the last 3 reporting periods (between 01/10/2023 and 30/06/2024).

LHD	Q4 2023							Q1 2024						Q2 2024							
	Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (without clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)		
		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)
ASNSW	0	0	-	-	0	-	-	1	1	1	14	1	100%	18	1	1	1	0	0	0%	234
CALVARY	12	9	75%	9	12	100%	11	9	8	89%	10	9	100%	12	9	4	44%	13	9	100%	16
CCLHD	11	9	82%	9	10	91%	28	7	6	86%	9	7	100%	33	12	10	83%	5	10	83%	49
FWLHD	0	0	-	-	0	-	-	0	0	0%	0	0	0%	0	0	0	-	-	0	-	-
HNELHD	50	27	54%	14	49	98%	30	22	18	82%	10	20	91%	25	34	28	82%	9	34	100%	25
ISLHD	19	19	100%	1	18	95%	8	4	4	100%	3	4	100%	8	19	18	95%	3	16	84%	24
JHFMHN	0	0	-	-	0	-	-	0	0	0	0	0	0%	0	2	2	1	4	1	50%	45
MLHD	10	9	90%	6	10	100%	32	2	2	100%	11	2	100%	21	8	8	100%	2	8	100%	30
MNCLHD	8	7	88%	7	7	88%	27	9	6	67%	9	9	100%	30	9	7	78%	10	8	89%	43
NBMLHD	20	7	35%	32	17	85%	58	6	2	33%	28	4	67%	77	9	2	22%	37	5	56%	68
NNSWLHD	4	3	75%	5	4	100%	39	2	1	50%	14	2	100%	57	0	0	-	-	0	-	-
NSLHD	60	36	60%	14	53	88%	38	48	26	54%	18	46	96%	39	52	38	73%	10	49	94%	34
NSWHPTH	2	0	0%	28	1	50%	74	7	2	29%	40	0	0%	132	9	2	22%	34	1	11%	141
SCHN	58	47	81%	9	52	90%	35	6	2	33%	21	3	50%	67	46	27	59%	15	34	74%	52
SESLHD	52	34	65%	14	41	79%	48	43	36	84%	9	38	88%	42	57	34	60%	12	54	95%	37
SLHD-CCD	29	23	79%	8	29	100%	25	18	12	67%	9	18	100%	26	28	25	89%	5	28	100%	19
SLHD-RPA	93	75	81%	8	90	97%	26	50	33	66%	13	49	98%	32	57	48	84%	5	57	100%	25
SNSWLHD	2	1	50%	38	1	50%	46	2	0	0%	165	0	0%	165	6	2	33%	23	4	67%	301
SVHN	34	25	74%	10	23	68%	54	22	18	82%	11	16	73%	54	42	32	76%	10	31	74%	48
SWSLHD	43	6	14%	54	14	33%	92	48	4	8%	55	9	19%	102	133	92	69%	15	97	73%	51
WNSWLHD	8	5	63%	13	7	88%	22	5	4	80%	9	3	60%	48	12	12	100%	5	11	92%	23
WSLHD	77	65	84%	9	63	82%	40	65	48	74%	12	45	69%	50	31	27	87%	9	23	74%	42
Total	592	407	69%	14	508	86%	40	376	233	62%	20	286	76%	51	576	419	73%	13	486	84%	45